艾司西酞普兰治疗中国抑郁症患者有效性和安全性的Meta分析

Efficacy and safety of escitalopram in the treatment of major depressive disorder in Chinese patients:a Meta-analysis

目的：利用Meta分析的方法评估艾司西酞普兰治疗中国抑郁症患者的有效性和安全性。方法：通过Medline、Embase、Cochrane Library、维普中文期刊数据库、中国期刊全文数据库、万方数据库等中外文数据库,搜索艾司西酞普兰治疗中国抑郁症患者的随机对照研究,应用Meta分析比较艾司西酞普兰和其他抗抑郁药物的有效率、治愈率及不良反应。数据采用固定效应模型。结果：共纳入8项高质量研究,其中艾司西酞普兰组共纳入549例患者,对照组纳入545例患者。研究显示,艾司西酞普兰治疗中国抑郁症患者的有效率（RR 1.00,95%CI 0.93～1.08）和治愈率（RR1.05,95%CI 0.94～1.17）与其他抗抑郁药物相比差异无统计学意义。艾司西酞普兰在治疗中国抑郁症患者时出现不良反应（恶心、口干、头晕、失眠、肝功能异常、其他胃肠道反应、心悸、乏力）的发生率和其他抗抑郁药相比差异无统计学意义。结论：通过系统归纳多项研究发现,艾司西酞普兰治疗中国抑郁症患者与对照组相比,其有效性与安全性均相当。

AIM： To evaluate the dfficacy and safety of escitalopram in Chinese patients with major depressive disorder（ MDD） using the Meta-analysis method. METHODS： A Meta-analysis was conducted to compare escitalopram with other antidepressants in Chinese patients with MDD patients. Major Western and Chinese electronic databases such as Medline, Embase, Cochrane Library, VIP（ VIP Database for Chinese Technical Periodicals）,CNKI（ China National Knowledge Infrastructure） and Wan Fang Database,were searched for randomized controlled trials（ RCTs） comparing escitalopram with other antidepressants in China. Response, remission,and adverse events were defined as primary outcomes. Data were combined with fixed effects model. RESULTS： A total of 8 studies were included. There were 549 patients in escitalopram and 545 patients in control group. No differences were found between escitalopram and other antidepressants in terms of response rate（ RR 1. 00,95% CI 0. 93-1. 08） and remission rate（ RR 1. 05,95% CI 0. 94- 1. 17） in Chinese patients with MDD. No differences were found between escitalopram and other antidepressants considering the rate of nausea, dry mouth,dizziness,insomnia,abnormal liver function,other gastrointestinal reaction,palpitation and fatigue in Chinese patients with MDD. CONCLUSION： By Meta-analysis,all the included studies indicate that escitalopram appears no statistically significant differences on its efficacy and safety to other antidepressants for Chinese MDD patients.